Results 11 to 20 of about 49,935 (237)

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats

Pharmaceutics, 2021
Fungal infections are prevalent in patients with immune diseases. Voriconazole, a triazole antifungal drug, inhibits the cytochromes CYP3A4 and CYP2C, and tofacitinib, a Janus kinase inhibitor for the treatment of rheumatoid arthritis, is metabolized by ...
Ji-Sang Lee, Hyo-Sung Kim, Yong-Seob Jung, Hyeon-Gyeom Choi, So-Hee Kim   +4 more
doaj   +2 more sources

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Arthritis Research & Therapy
Background Data on treatment switching directly from tumor necrosis factor inhibitors to tofacitinib in psoriatic arthritis (PsA) are limited. This post hoc analysis assessed efficacy and safety outcomes in patients with PsA who directly switched to ...
Dafna D. Gladman, Peter Nash, Philip J. Mease, Oliver FitzGerald, Stephanie Duench, Mary Jane Cadatal, Karim R. Masri   +6 more
doaj   +2 more sources

Off-target profiling of tofacitinib and baricitinib by machine learning: a focus on thrombosis and viral infection. [PDF]

, 2021
Objectives: There are no clear on-target mechanisms that explain the increased risk for thrombosis and viral infection or reactivation associated with Janus kinase (JAK) inhibitors.
Maria Luisa , Faquetti, Francesca , Grisoni, Petra, Schneider, Andrea, Burden, Gisbert , Schneider   +4 more
core   +2 more sources

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

Rheumatology and Therapy, 2022
Introduction This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs. Methods Available data from phase 1, randomized phase 2/3/
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen   +14 more
doaj   +1 more source

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Arthritis Research & Therapy, 2022
Background This study examined the time to clinically meaningful response in patients with active psoriatic arthritis treated with tofacitinib, adalimumab, or placebo switching to tofacitinib.
Dafna D. Gladman, Laura C. Coates, Joseph Wu, Lara Fallon, Elizabeth D. Bacci, Joseph C. Cappelleri, Andrew G. Bushmakin, Philip S. Helliwell   +7 more
doaj   +1 more source

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis

RMD Open, 2022
Objective Post hoc analysis of pooled data from nine randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) on residual pain in patients with
Maxime Dougados, Peter C Taylor, Clifton O Bingham, Lisy Wang, Lara Fallon, Satrajit Roychoudhury, Yves Brault, Meriem Kessouri   +7 more
doaj   +1 more source

Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial

Transplantation Direct, 2018
Background. Tofacitinib is an oral Janus kinase inhibitor. This open-label, long-term extension (LTE) study (NCT00658359) evaluated long-term tofacitinib treatment in stable kidney transplant recipients (n = 178) posttransplant. Methods.
Stephan Busque, MD, MSc, FRCSC, Flavio G. Vincenti, MD, Helio Tedesco Silva, MD, Philip J. O’Connell, MD, Atsushi Yoshida, MD, John J. Friedewald, MD, Steven M. Steinberg, MD, Klemens Budde, MD, Emine N. Broeders, MD, Yon Su Kim, MD, Carolyn M. Hahn, BA, Huihua Li, MS, Gary Chan, PharmD   +12 more
doaj   +1 more source

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

RMD Open, 2021
Background Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib.Methods Data from two trials ...
Roy Fleischmann, Peter C Taylor, Kurt de Vlam, Joseph C Cappelleri, Alexis Ogdie, Lara Fallon, John Woolcott, Valderilio Azevedo, Andrew G Bushmakin   +8 more
doaj   +1 more source

Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes

Acta Dermato-Venereologica, 2018
Tofacitinib is a Janus kinase (JAK) inhibitor, which has shown efficacy in treating psoriasis. The mode of action of tofacitinib is not completely understood but it has been thought to be mediated by the inhibition of CD4+ T-cell activation.
Ankit Srivastava, Mona Ståhle, Andor Pivarcsi, Enikö Sonkoly   +3 more
doaj   +1 more source

Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2021
Objective: To explore the survival benefit of tofacitinib in addition to dexamethasone in hospitalized patients treated for coronavirus disease 2019 (COVID-19)–related pneumonia.
Maroun E. Hayek, MD, Michael Mansour, MD, Harrison Ndetan, MPH, MD, PhD, Quentin Burkes, PharmD, Robert Corkern, MD, Ammar Dulli, MD, Reya Hayek, BS, Karim Parvez, MD, Satwinder Singh, MD   +8 more
doaj   +1 more source